Over the last two decades, clinicians and laboratories gained greater understanding about genomic alterations in non-small cell lung cancer (NSCLC). With this wealth of knowledge comes the need for adapting protocols to optimise testing for disease diagnosis and treatment.

In this recent webinar collaboration between AstraZeneca and Roche Diagnostics Asia Pacific, Dr Chih-Hsi Kuo, director of the Department of Thoracic Medicine at Chang Gung Memorial Hospital in Taiwan, shares his clinical experiences using liquid biopsy methods. Dr Kuo highlights four main advantages of this approach:

1.    Circumvent the issue of tumour heterogeneity
2.   Complement traditional tissue biopsy in testing and finding T790M mutations
3.   Contribute to the study of complicated genomic alterations after drug resistance arises
4.   Detect minimal residual disease in the case of disease recurrence or as an indicator of other cancers

Watch the full presentation below.